PURA - Puration Reports First Revenue From Patented Cannabis Extraction And Progress Toward $3 Million Annual Revenue Target
May 18 2017 - 8:10AM
InvestorsHub NewsWire
Dallas, Texas – May 18,
2017 -- InvestorsHub NewsWire -- – Puration, Inc. (USOTC:
PURA) has published an online on demand earnings presentation
reviewing the Company’s first quarter 2017 financial report.
In addition to a review of the most recent financial results, which
highlights the Company’s first reported revenue from its patented
cannabis extraction business, the report also includes details
about the pending transaction with American Cannabis Innovations
Conglomerated with specific mention that PURA stock will remain
listed on the OTC Markets and will not be subject to a reverse
split. The report also includes details about the Company’s
plans with NCM Biotech to pursue the development of cannabis
pharmaceuticals. Furthermore, the report includes the latest
updates on the Companies three cannabis infused beverage contracts
and its target $3 million in annual revenue.
REVIEW THE ENTIRE PURA EARNINGS REPORT
To learn more about
Puration:
purationinc.com
To learn more about NCM
Biotech:
ncmbiotech.com
Disclaimer/Safe Harbor: This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies’ contracts, the companies’ liquidity position, the
companies’ ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure or prevent any disease.
Puration Contact:
Brian Shibley, CEO
info@purationinc.com
+1-214-937-9097
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024